Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
2/5/2026
Everest Medicines Licenses Micot's MT1013 for SHPT in China and Asia-P...
2/5/2026
Angitia Biopharma Raises $130M in Series D Financing to Advance Pipeli...
2/5/2026
Eisai Secures Exclusive Rights to Henlius' Anti-PD-1 Antibody Serpluli...
2/5/2026
iMBioRay Raises Nearly CNY 200M Series B to Advance NK Cell Therapy P...
2/5/2026
Shanghai Pharma Exits BMS China, Closing a Chapter for JV Pharma in Ch...
2/5/2026
2026 National Conference on Drug Registration and Post-Market Regulati...
2/5/2026
CDE Issues Trial Guideline for Neuropathic Pain Drug Development
2/5/2026
CDE Issues Technical Guideline for Clinical Trials of Chronic Insomnia...
2/4/2026
Innovent Advances IL-15 Antibody IBI3013 Into Clinical Trials for Viti...
2/4/2026
China Clears BeBetter Med Dual-Target siRNA Therapy for Combined Hyper...
2/4/2026
Vertex Takes Global Control of WuXi Biologics Trispecific T-Cell Engag...
2/4/2026
Novartis Secures Global Rights to SciNeuro’s Next-Gen Alzheimer’s An...
2/4/2026
Chia Tai Tianqing's Anlotinib New Indication Application Rejected
2/4/2026
China Gene‑Editing Startup AccurEdit Raises $75M to Advance Promising...
2/4/2026
WuXi Biologics and Sinorda Join Forces to Develop Bispecific Antibody ...
2/4/2026
Almirall's Seysara Approved in China for Moderate-to-Severe Acne
2/4/2026
Ant Group's AI Health Chatbot Surges in Popularity Amid China's Overbu...
2/4/2026
China's Health Insurance Market Poised for $596B Surge by 2033
2/4/2026
Bayer's Nubeqa Gains Third Approval in China for Advanced Prostate Can...
2/4/2026
CMS Gets Green Light from NMPA to Launch Trials for Novel Kidney Disea...
2/3/2026
NMPA Logs Wave of Novel Drug Approvals and Clinical Trial Clearances L...
2/3/2026
Beijing-Based PrimeGenX Therapeutics' HKSE IPO Application Accepted
2/3/2026
HSG Completes Global Acquisition of Avelox and Launches Anti-Infective...
2/3/2026
New Indication for Novartis' Secukinumab in Non-Radiographic Axial Spo...
2/3/2026
Zonsen PepLib Signs Global Peptide R&D Deal with Eli Lilly
2/3/2026
Siran Bio Advances Global Clinical Development of ALK7 siRNA SA030
2/3/2026
Hengrui's Camrelizumab Combo Accepted by FDA for First-Line Liver Canc...
2/3/2026
Zhiben Wins China IND Approval for AR Molecular Glue Degrader ZB-002 i...
2/3/2026
Newsoara Expands Global Footprint With $135M Deal for vTv's Inflammati...
2/3/2026
China and USFDA Officials Pledge to Deepen Regulatory Cooperation at B...
Page:
3
/
60
Total number of articles:
1780
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit